Full Text View
Tabular View
No Study Results Posted
Related Studies
Pegasys® in Patients With Myeloproliferative Diseases
This study is currently recruiting participants.
Study NCT00452023   Information provided by M.D. Anderson Cancer Center
First Received: March 22, 2007   Last Updated: July 14, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myeloproliferative Disorders
Additional conditions recognized in this trial
Disease
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Leukemia
Leukemia, Myeloid
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
IFN-alpha2a
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon-alpha
Interferons
Peginterferon alfa-2a
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services